Recurrent Acute Myeloid Leukemia

Oncology·MeSH: Leukemia, Myeloid, Acute

Prevalence

6.0 / 100K

Incidence

4.3 / 100K/yr

5 drugs in development·2 companies·11 clinical trials

Drug Pipeline by Phase

Compare drugs

Liposome-encapsulated Daunorubicin-Cytarabine vs Vincristine Sulfate LiposomeLiposome-encapsulated Daunorubicin-Cytarabine vs CytarabineLiposome-encapsulated Daunorubicin-Cytarabine vs Etoposide Phosphate

Frequently asked questions

How many drugs are in development for Recurrent Acute Myeloid Leukemia?

BioSniper tracks 5 drugs in development for Recurrent Acute Myeloid Leukemia across 2 companies.

How many clinical trials target Recurrent Acute Myeloid Leukemia?

There are 11 clinical trials targeting Recurrent Acute Myeloid Leukemia tracked by BioSniper.

What is the prevalence of Recurrent Acute Myeloid Leukemia?

The estimated prevalence of Recurrent Acute Myeloid Leukemia is approximately 6.0 per 100,000 population.

Deep-dive into Recurrent Acute Myeloid Leukemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Recurrent Acute Myeloid Leukemia — Drugs in Development & Clinical Trials | BioSniper